glut1

STF-31 is an inhibitor of glucose transporter 1 (GLUT1) with IC50 of 1 μM.

BAY-876 is an orally active, selective inhibitor of glucose transporter 1 (GLUT1, IC50= 2 nM), exhibiting over 130-fold greater selectivity for GLUT1 than GLUT2, GLUT3, and GLUT4. It also inhibits glycolytic metabolism and ovarian cancer growth.

WZB117 is a Glucose Transporter 1 (GLUT1) inhibitor. when IC50 of WZB117 approximate 10 μM, it inhibits lung cancer A549 cells and breast cancer MCF7 cells proliferation.

Lavendustin B is a Tyrosine Kinase Inhibitor and an inhibitor of HIV-1 integrase (IN) interaction with its cognate cellular cofactor, lens epithelium-derived growth factor (LEDGF/p75).

GLUT4-IN-2 is a specific GLUT4 inhibitor that inhibits GLUT1 and GLUT4.GLUT4-IN-2 has antitumor activity, induces apoptosis and cell cycle arrest, and can be used for cancer research.

Fasentin (N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide) is an inhibitor of GluT1.

hydrocotarnine is an inhibitor of Cbl.

KL-11743 specifically blocks glucose metabolism, triggering an acute collapse in NADH pools and a striking accumulation of aspartate, indicating a dramatic shift toward oxidative phosphorylation in the mitochondria.

Marein shows neuroprotective effect on PC12 cell damage induced by methylglyoxal, which is due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway, it may be a potent compound for preventing/counteracting diabetic e

GLUT1/EGFR-IN-1 (compound H) is a potent inhibitor of both GLUT1 and EGFR. It targets the ATP-binding site of the EGFR tyrosine kinase and inhibits GLUT1-mediated energy metabolism, resulting in reduced ATP, MMP, intracellular lactate, and nuclear translocation of EGFR. GLUT1/EGFR-IN-1 is applicable in the research of nasopharyngeal carcinoma (NPC) and triple-negative breast cancer (TNBC).

GLUT1-IN-1, a glucose transporter 1 (GLUT1) inhibitor, possesses specific inactivation capability for GLUT1. This compound demonstrates concentration-dependent cytotoxicity towards HeLa, A549, and HepG2 cells, with IC50 values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. It is utilized in the research of photodynamic therapy (PDT) and several cancers [1].

GLUT1-IN-3 (Compd 4b), a compound under investigation for type 1 glucose transporter deficiency syndrome, effectively inhibits seizures [1].

OSS_128167 (SIRT6-IN-1) is a specific SIRT6 inhibitor, and for SIRT6(IC50=89 μM), SIRT1(IC50=1578 μM) and SIRT2(IC50=751 μM).

GLUT inhibitor-1 is an orally active GLUT inhibitor with IC50 s of 242 nM and 179 nM for GLUT1 and GLUT3. GLUT inhibitor-1 can be used in studies about cancers and autoimmune diseases.

4,6-O-Ethylidene-α-D-glucose is a glucose derivative that competitively inhibits the extracellular binding site of glucose transporter 1 (GLUT1), with a Ki of 12 mM for the transport of wild-type 2-deoxy-D-glucose.

GLUT-1-IN-4 (Compound 13) is an inhibitor of the GLUT-1 glucose transporter that depends on the p53 protein. It suppresses the proliferation of various cancer cells at submicromolar IC50 levels. Additionally, GLUT-1-IN-4 can halt the cell cycle, induce oxidative stress, and promote apoptosis (cell death).

Protein O-Glucosyltransferase 1 is a glucosyltransferase that modifies the Notch signaling pathway by attaching glucose to serine residues within Notch.

Triheptanoin (IND 106011) is a fatty acid metabolic modulator. It potentially for the treatment of fatty acid oxidation disorders and GLUT1.

PT2399 is a potent, selective, orally available HIF-2α antagonist that directly binds to the PAS B domain of HIF-2α (IC₅₀ = 6 nM). PT2399 exhibits antitumor activity. PT2399 specifically blocks the heterodimerization of HIF-2α and HIF-1β, thereby inhibiting the expression of downstream target genes such as VEGF and GLUT1, and exerts its antitumor effects.

AS1949490 activated glucose metabolism via up-regulation of GLUT1 gene in L6 myotubes[1][2]. AS1949490 is a potent and selective SHIP-2 (SH2 domain-containing inositol 5′ phosphatase 2) inhibitor, with an IC50 of 620 nM.

(Rac)-Glutipyran is a broad-spectrum GLUT inhibitor targeting both GLUT1 and GLUT3. This compound inhibits glucose uptake and significantly impedes the growth of various cancer cells, particularly demonstrating substantial inhibition of PANC-1 cell growth (IC50=1.8 μM) and glucose uptake (IC50=0.13 μM).

Rapaglutin A is a glucose transporter (GLUT) inhibitor. It acts as a pan-GLUT inhibitor for the class I isomers GLUT1, GLUT3, and GLUT4, with an IC50 of 12 nM. Additionally, Rapaglutin A inhibits the proliferation of A549 cells.

WZB117-PPG is an inhibitor of glucose transporter 1 (GLUT1) with anticancer properties. Under visible light irradiation, this compound demonstrates significant photolytic efficiency and cytotoxicity toward cancer cells.

3-Fluoro-evodiamine glucose (Compound 8) is an evodiamine-glucose conjugate. It enhances the expression of glucose transporter 1 (GLUT1) and inhibits topoisomerase I/II activity. Additionally, 3-Fluoro-evodiamine glucose induces apoptosis and causes cell cycle arrest at the G2/M phase. This compound demonstrates anti-tumor activity both in vivo and in vitro, with no significant toxicity observed.